{"brief_title": "Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis", "brief_summary": "The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo.", "condition": "Rheumatoid Arthritis", "intervention_type": "Drug", "intervention_name": "ABA, open-label (OL)", "description": "Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months", "arm_group_label": "Abatacept (open-label)", "other_name": "Orencia", "criteria": "Inclusion Criteria: - Diagnosis of Rheumatoid Arthritis - At least 3 months prior treatment with Methotrexate (MTX) - At least 10 swollen joints and 12 tender joints and C-Reactive Protein of at least 1 mg/dl - Washout required for other disease modifying anti-rheumatic drugs (DMARDS) Exclusion Criteria: - participants who have failed more than 3 DMARDs - participants previously treated with an approved biologic drug - History of cancer in the last 5 years - Severe or recurrent bacterial infection - Any previous or current medical conditions that are contraindications to the use of TNF blocking agents - Women of Child Bearing Potential", "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "id": "NCT00095147.xml"}